National nanotechnology strategy looks to boost biotech
07 December, 2012 by Tim DeanThe Australian Academy of Science’s National Nanotech Research Strategy aims to boost investment and research in nanotech, including in nanobiotechnology and nanomedicine.
Starpharma's anti-cancer docetaxel beats Taxotere in animals
06 December, 2012 by Dylan Bushell-EmblingAnimal trials of Starpharma (ASX:SPL) dendrimer-docetaxel showed a significant reduction in tumour cell survival compared to original formula Taxotere.
Trans Tasman joint therapeutic products scheme progresses
06 December, 2012 by AusBiotechProgress towards a joint Australia New Zealand therapeutic products regulatory scheme continues with the second meeting of the Australia New Zealand Therapeutic Products Agency (ANZTPA) Implementation Ministerial Council last week.
Sirtex to investigate nanoparticle anti-cancer technology
05 December, 2012 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) has entered a research collaboration with Singapore's SingHealth to explore the applications of Carbon Gage Nanoparticles in combating difficult-to-treat cancers.
CSL rebrands Australian businesses
05 December, 2012 by Tim DeanIconic Australian biotech, CSL, is rebranding its two core business units covering plasma and pharmaceuticals in line with a company global reorganisation.
Biotech Christmas celebrations continue around the country
04 December, 2012 by AusBiotechWhile some states have already begun Christmas celebrations, three states are about to host AusBiotech's free Christmas events as their final networking events of 2012.
Osprey enrols first patient for diabetic limb recovery trial
04 December, 2012 by Dylan Bushell-EmblingOsprey Medical (ASX:OSP) has signed up the first of a planned 25 patients for an Australian trial of its Limb Recovery System in diabetic patients with limb infections.
Phosphagenics expanding pain patch program
03 December, 2012 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) has resolved crystallisation issues holding up its TPM-Oxycodone pain patch project and expanded the program to include another opioid-based product.
Iluvien knocked back again on reimbursement in the UK
03 December, 2012 by Tim DeanThe UK’s reimbursement agency has knocked back Illuvien again, saying its benefits do not justify the price.
Starpharma emphasises portfolio after VivaGel trial fail
30 November, 2012 by Tim DeanFollowing news that a phase III trial of VivaGel failed to reach its primary end point, Starpharma (ASX:SPL) has emphasised the potential of its platform technology across multiple applications.
Biotech women in leadership
29 November, 2012 by AusBiotechWomen in biotechnology have featured strongly in the “2012 Australia Census of Women in Leadership”, with biotech CEOs making up 25 per cent of the female CEOs of ASX 500 companies.
Allied Healthcare’s CardioCel aids heart valve reconstruction
28 November, 2012 by Dylan Bushell-EmblingA pre-clinical trial of Allied Healthcare's (ASX:AHZ) CardioCel in valve reconstruction showed evidence of new tissue growth near the parch at eight-month follow-up.
Genetic Technologies tanks as CEO resigns in protest over board spill
28 November, 2012 by Tim DeanTumult has struck Genetic Technologies (ASX:GTG) as CEO Paul MacLeman resigns at the annual general meeting yesterday in protest over a board spill.
Starpharma enters trading halt ahead of VivaGel trial results
28 November, 2012 by Tim DeanTrading in Starpharma (ASX:SPL) has been halted ahead of an announcement by the company of two phase III studies of its VivaGel treatment for bacterial vaginosis.
CSL at record high on profit forecast
27 November, 2012 by Dylan Bushell-EmblingCSL (ASX:CSL) shares surged to a record $50+ after the company hiked its FY13 profit forecast by seven percentage points.
